SAN Sanofi

Sanofi: Information concerning the total number of voting rights and shares – January 2023

Sanofi: Information concerning the total number of voting rights and shares – January 2023

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi

a French société anonyme with a registered share capital of 2,521,494,572 €

Registered office : 46, avenue de la Grande Armée - 75017 Paris - France

Registered at the Paris Commercial and Companies Registry under number 395 030 844

Date 



Total number of

issued shares



 		Number of real

voting rights

(excluding treasury shares)		Theoretical number of

voting rights

(including treasury shares)*
January 31, 20231,260,835,8081,406,293,2901,418,488,760

* Pursuant to article 223-11 of the Règlement général de l’Autorité des Marchés Financiers.

This information is also available on the internet website of sanofi under « Regulated Information in France »:

Investor Relations Department

e-mail:



 



 

Attachment



EN
15/02/2023

Underlying

SANSanofi

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

Research Department
  • Research Department
EUR 100.00
SAN SANOFI
GRF SM Grifols (GRF SM...

INFORME DIARIO 30 MAYO (ANÁLISIS BANCO SABADELL)

COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: GRIFOLS. EUROPA: SANOFI. ¿Portazo a los aranceles? En una jornada de más a menos las bolsas europeas, a excepción del Ibex, terminaron con ligeras caídas tras el bloqueo a los aranceles recíprocos que dictaminó un tribunal de EE.UU. En el STOXX 600 la mayoría de los sectores (15/20) cerraron con pérdidas, lideradas por los defensivos Utilites y Hogar frente a las mayores ganancias de Bancos y R. Básicos. Por el lado macro, en España las ventas al po...

SAN SANOFI
GRF SM GRIFOLS (GRF SM)
05/30/25 May 30, 2025 1 ES
 PRESS RELEASE
Free
SAN SANOFI

Press Release: Itepekimab met the primary endpoint in one of two COPD ...

Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefitAERIFY-2 study, a second Phase 3 study, did not meet the primary endpoint despite a benefit seen earlier in the studyItepekimab was generally well tolerated in both AERIFY-1 and AERIFY-2Sanofi and Regeneron are assessing th...

May 30, 2025 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : L’itépekimab a satisfait au critère d’évaluatio...

Communiqué de presse : L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO L’étude AERIFY-1 a atteint son objectif principal, à savoir une réduction statistiquement significative des exacerbations modérées ou sévères chez les anciens fumeurs, et a apporté un bénéfice cliniquement significatif.L’étude AERIFY-2, seconde étude de phase 3, n’a pas atteint son objectif principal, malgré un bénéfice observé plus tôt dans l’étude. Un...

May 30, 2025 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Press Release: Beyfortus public health advantage bolstered by first re...

Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs Late-breaking data show infant respiratory syncytial virus (RSV) hospitalizations reduced by 69% in Spain following Beyfortus-only immunization targeted to all infants and 26.7% in the UK following RSVpreF-only maternal vaccination Newly presented durability data show Beyfortus sustained efficacy of 83% through six months in babies...

May 29, 2025 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : L’avantage de Beyfortus pour la santé publique ...

Communiqué de presse : L’avantage de Beyfortus pour la santé publique renforcé par la première comparaison en situation réelle des programmes de vaccination infantile et maternelle contre le VRS L’avantage de Beyfortus pour la santé publique renforcé par la première comparaison en situation réelle des programmes de vaccination infantile et maternelle contre le VRS Des données de dernière minute montrent que les hospitalisations dues au virus respiratoire syncytial (VRS) chez les nourrissons ont diminué de 69 % en Espagne après vaccination par Beyfortus uniquement ciblant tous les nourrisso...

May 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch